IL1B and asbestosis: Our case does not provide indication of the effects of anti-IL-1 beta targeted therapy on the progression of lung fibrosis, and does not allow definitive conclusions to be drawn, but may suggest a new perspective for the treatment of systemic autoimmune features of asbestosis and, possibly, of lung involvement.